L-arginine in Severe Asthma Patients Grouped by Exhaled Nitric Oxide Levels

• Status: Completed
• Trial end date: 2019-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The major impact of this study will be to identify the adult severe asthma cohort that will benefit from supplemental L-arginine therapy. The investigators hypothesize that a subset of adult severe asthma patients will respond to supplemental L-arginine and derive clinical benefit from the addition of this therapy to standard-of-care asthma medications. The investigators hypothesize that the patients that benefit most will have low exhaled nitric oxide concentrations (< 20 ppb) at baseline.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nicholas Kenyon; University of California, Davis
• Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
• Treatments: Nitric Oxide

Criteria

Inclusion Criteria:

• Adults >18 yrs of age

• Diagnosis of severe asthma based on American Thoracic Society Workshop definition (Am J Respir Crit Care Med 2000; 162:2341)

• Active asthma medications of high dose inhaled corticosteroids plus long-acting beta agonist

• History of recent asthma exacerbations or Asthma control test score < 20/25

Exclusion Criteria:

• <19 yrs of age

• Forced expiratory volume 1sec <30% predicted

• Pregnant or nursing women

• Current smokers or smoking history > 15 pack years

• Actively taking or known intolerance to L-arginine